Psyence Biomedicals Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
NEW YORK, March 06, 2024 - Psyence Biomedical Ltd (NASDAQ:PBM) (Psyence Biomed or the Company) is excited to announce a significant achievement for its wholly-owned subsidiary, Psyence Australia (Pty) Ltd (Psyence Australia). The Australian Health Research Ethics Committee (HREC) has granted full approval for Psyence Australia to commence its anticipated Phase IIb study in Melbourne, Australia. This ground-breaking study aims to investigate the potential use of nature-derived psilocybin as a treatment for Adjustment Disorder in individuals experiencing distress after a recent cancer diagnosis in the palliative care context.
Palliative care is a critical aspect of healthcare worldwide, with an estimated 56.8 million people requiring this specialized form of care annually. Among these patients, a substantial proportion grapple with severe psychosocial distress following their cancer diagnosis. Adjustment Disorder due to a recent cancer diagnosis poses significant challenges for both patients and their healthcare providers, impacting their emotional well-being, daily functioning, and ability to cope during treatment and life after cancer.
Recognizing the urgent need for enhanced treatment options, Psyence Australia is spearheading this Phase IIb study, which will assess the feasibility and efficacy of using nature-derived psilocybin to alleviate Adjustment Disorder symptoms in palliative care patients. Psilocybin, a naturally occurring compound found in various species of hallucinogenic mushrooms, has shown promising results in studies exploring its therapeutic potential for various mental health conditions, including depression, anxiety, and substance use disorders.
Under the guidance of esteemed researchers and medical professionals, the study will employ rigorous scientific protocols to evaluate the effectiveness, safety, and tolerability of psilocybin-assisted therapy. It will involve a randomized, double-blind, placebo-controlled design, ensuring unbiased and reliable results.
Psyence Australia’s Phase IIb study represents a significant step forward in advancing the field of psychotherapeutic interventions for patients navigating the emotional complexities of palliative care. By harnessing the potential of psilocybin in conjunction with therapy, this research aims to provide new avenues of healing and relief for individuals burdened by Adjustment Disorder.
This HREC approval is a critical milestone and a testament to the scientific integrity, ethical considerations, and robustness of the study’s design. It underscores the commitment of Psyence Australia and its dedicated team to conducting responsible research and driving innovation in mental health care.
As Psyence Australia gears up to embark on this groundbreaking investigation, the team remains poised to make a substantial impact in the realm of palliative care and mental health interventions. Through rigorous study design and collaboration with healthcare professionals, Psyence Australia aims to contribute to the growing body of evidence supporting the utility of psilocybin therapies in improving the quality of life for patients facing Adjustment Disorder after a recent cancer diagnosis.
With this Phase IIb study now underway, Psycene Australia’s commitment to advancing mental health initiatives remains steadfast, offering new hope and possibilities for individuals struggling with Adjustment Disorder in the palliative care setting.
Comments